Adynamic bone disease and malnutrition-inflammation-cachexia syndrome [5]

Kidney International

Volumn 71, Issue 12, 2007, Pages 1326-

  Heaf, J ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D;

BONE DISEASE; CACHEXIA; COMORBIDITY; DIALYSIS; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; INFLAMMATION; LETTER; MALNUTRITION; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL;

BONE DISEASES; CACHEXIA; HUMANS; INFLAMMATION; MALNUTRITION; PARATHYROID HORMONE; RENAL DIALYSIS; SURVIVAL; SYNDROME;

EID: 34249986387     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002257     Document Type: Letter

References (6)

1. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
2. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S125-S126.
3. Heaf JG, Løkkegaard H. Parathyroid hormone during maintenance dialysis: role of low calcium dialysate, plasma albumin and age. J Nephrol 1998; 11: 203-210.
4. Heaf JG. Causes and consequences of adynamic bone disease. Nephron 2001; 88: 97-106.
5. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
6. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005)); 16: 1115-1125.